Modern potentials for the treatment of ankylosing spondylitis


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Modern pharmacotherapy opens wide opportunities to influence the various clinical manifestations of ankylosing spondylitis (AS). Along with the traditional treatment regimens, new classes of drugs that can improve the condition of patients and slow the progression of the disease emerge. The introduction of tumor necrosis factor α (TNF-α) inhibitors into clinical practice can be considered as a great progress in the treatment of AS. Wide application of genetically engineered biological agents in clinical practice does not preclude the search for other available therapeutic approaches, associated with less severe immunosuppression, good tolerability, a lower cost.

全文:

受限制的访问

作者简介

A. Godzenko

Email: alla1106@mail.ru

参考

  1. Feldtkeller E. ASIF News. 2004;2(1):7-8.
  2. Wanders A., Heijde Dv., Landewe R., et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52(6): 1756-65.
  3. Бочкова А.Г. Роль глюкокортикоидов в лечении спондилоартритов. Современная ревматология, 2011;1:76-9.
  4. Munos-Fernandes S., Hidalgo V., Fernandes-Melon J. Sulfasalasine reduces the number of flares of acute anterior uveitis over a one-year period. J. Rheumatol. 2003;30(6):1277-79.
  5. van der Heijde D., Sieper J., Maksymowych W. P., et al. (Second) Update of the ASAS recommendations on the use of TNF-blockers in ankylosing spondylitis. Arthr. Rheum. 2009;60(Suppl 10): 1790.
  6. Румянцева О.А. Эффективность и безопасность инфликсимаба у больных анкилозирующим спондилитом и его влияние на лабораторные маркеры воспаления. Автореферат дис. канд. мед. наук, М., 2010. 28 с.
  7. Braun J., Deodhar A., Dijkmans B., et al. Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthr. Rheum. 2008;59(9):1270-78.
  8. Braun J., Baraliakos X., Listing J., et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann. Rheum. Dis. 2008;67(3):340-45.
  9. Румянцева О.А., Бочкова А.Г., Левшакова А.В., Эрдес Ш.Ф., Насонов Е.Л. Опыт длительной терапии инфликсимабом у больных анкилозирующим спондилитом. Научно-практическая ревматология. 2010;6:16-22.
  10. Tenga G., Goëb V., Lequerre T., et al. A 3 mg/ kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs. Joint Bone Spine. 2011;78(1):50-5.
  11. Бочкова А.Г., Рукмянцева О.А., Дубинина Т.В. и др. Первый опыт применения адалимумаба у больных анкилозирующим спондилитом: клиническое и МРТ-сопоставление результатов терапии. Научно-практическая ревматология. 2010;1:67-74.
  12. Haibel H., Rudwaleit M., Listing J., et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthr. Rheum. 2008;58(7): 1981-91.
  13. van der Heijde D., Schiff M. H., Sieper J., et al. A TLAS Study Group. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann. Rheum. Dis. 2009;68(6):922-29.
  14. Rudwaleit M., Rodevand E., Holck P. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann. Rheum. Dis. 2009;68(5):696- 701.
  15. Liu Y.F., Dong H., Tu S.H., et al. Etanercept in the treatment of ankylosing spondylitis: A systematic review and meta-analysis. Exp. Ther. Med. 2014;8(5): 1585-92.
  16. Dougados M., van der Heijde D., Sieper J., et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthr. Rheum. 2014;66(8):2091-102.
  17. Martin-Mola E., Sieper J., Leirisalo-Repo M., et al. Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin. Exp. Rheumatol. 2010;28(2):238-45.
  18. Taban M., Dupps W.J., Mandell B. Etanercept-associated inflammatory eye diseas: case report and review of the literature. Ocul. Immunol. Inflamm. 2006;14(3):145-50.
  19. Inman R.D., Davis J.C., van der Heijde D. Efficacy and safety of golimumab in patients with ankylosing ности воздействия на различные клинические проявления АС. Наряду с традиционными схемами лечения появляются новые классы препаратов, способные улучшать состояние пациентов, а, возможно, и замедлять прогрессирование заболевания. spondylitis results of a randomized, double-blind, placebo-controlled phase III trial. Arthr. Rheum. 2008;58:3402-12.
  20. Braun J., Deodhar A., Inman R.D., et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis 104-week results of the GO-RAISE study. Ann. Rheum. Dis. 2012;71:661-67.
  21. Braun J., Baraliakos X., Hermann K.G., et al. The effect of two golimumab doses on radiographic progression in ankylosin g spondylitis: results through 4 years of the GO-RAISE trial. Ann. Rheum. Dis. 2014;73:1107-13.
  22. Palframan R., Ayrey M., Moore A., Vugler A., Nesbitt A. Use of biofluorescence imaging to comparethe distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed pawsof mice with collagen-induced arthritis. J. Immunol. Meth. 2009;348:36-41.
  23. Dhillon S. Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis. Drugs. 2014;74(9):999-1016.
  24. Sieper J., Landewe R., Rudwaleit M., et al. Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial. Arthr. Rheum. 2015;67(3):668-77.
  25. Haroon N., Inman R.D., Learch T.J., et al. The impact of TNF inhibitors on radiographic progression in ankylosing spondylitis. Arth. Rheum. 2013;65(10):2645-54.
  26. Baeten D., Baraliakos X., Braun J., et al. Antiinterleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebocontrolled trial. Lancet. 2013;382(9906): 1705-13.
  27. Colbert R.A., Ward M.M. 17 and 23: prime numbers for ankylosing spondylitis? Lancet. 2013;382(9906): 1682-83.
  28. Pathan E., Abraham S., Van Rossen E., et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann. Rheum. Dis. 2013;72(9): 1475-80.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##